VKTX Long Put Strategy

VKTX (Viking Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VKTX (Viking Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $3.68B, a beta of 0.71 versus the broader market, a 52-week range of 22.959-43.15, average daily share volume of 2.4M, a public-listing history dating back to 2015, approximately 45 full-time employees. These structural characteristics shape how VKTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.71 places VKTX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a long put on VKTX?

A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.

Current VKTX snapshot

As of May 15, 2026, spot at $30.42, ATM IV 57.57%, IV rank 8.60%, expected move 16.50%. The long put on VKTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this long put structure on VKTX specifically: VKTX IV at 57.57% is on the cheap side of its 1-year range, which favors premium-buying structures like a VKTX long put, with a market-implied 1-standard-deviation move of approximately 16.50% (roughly $5.02 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VKTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on VKTX should anchor to the underlying notional of $30.42 per share and to the trader's directional view on VKTX stock.

VKTX long put setup

The VKTX long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VKTX near $30.42, the first option leg uses a $30.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VKTX chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VKTX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Put$30.00$1.56

VKTX long put risk and reward

Net Premium / Debit
-$155.50
Max Profit (per contract)
$2,843.50
Max Loss (per contract)
-$155.50
Breakeven(s)
$28.45
Risk / Reward Ratio
18.286

Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.

VKTX long put payoff curve

Modeled P&L at expiration across a range of underlying prices for the long put on VKTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price% From SpotP&L at Expiration
$0.01-100.0%+$2,843.50
$6.73-77.9%+$2,171.01
$13.46-55.8%+$1,498.52
$20.18-33.6%+$826.02
$26.91-11.5%+$153.53
$33.63+10.6%-$155.50
$40.36+32.7%-$155.50
$47.08+54.8%-$155.50
$53.81+76.9%-$155.50
$60.53+99.0%-$155.50

When traders use long put on VKTX

Long puts on VKTX hedge an existing long VKTX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying VKTX exposure being hedged.

VKTX thesis for this long put

The market-implied 1-standard-deviation range for VKTX extends from approximately $25.40 on the downside to $35.44 on the upside. A VKTX long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long VKTX position with one put per 100 shares held. Current VKTX IV rank near 8.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on VKTX at 57.57%. As a Healthcare name, VKTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VKTX-specific events.

VKTX long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VKTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VKTX alongside the broader basket even when VKTX-specific fundamentals are unchanged. Long-premium structures like a long put on VKTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current VKTX chain quotes before placing a trade.

Frequently asked questions

What is a long put on VKTX?
A long put on VKTX is the long put strategy applied to VKTX (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With VKTX stock trading near $30.42, the strikes shown on this page are snapped to the nearest listed VKTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are VKTX long put max profit and max loss calculated?
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the VKTX long put priced from the end-of-day chain at a 30-day expiry (ATM IV 57.57%), the computed maximum profit is $2,843.50 per contract and the computed maximum loss is -$155.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a VKTX long put?
The breakeven for the VKTX long put priced on this page is roughly $28.45 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VKTX market-implied 1-standard-deviation expected move is approximately 16.50%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long put on VKTX?
Long puts on VKTX hedge an existing long VKTX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying VKTX exposure being hedged.
How does current VKTX implied volatility affect this long put?
VKTX ATM IV is at 57.57% with IV rank near 8.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related VKTX analysis